Saint Maria Hospital — Clinical Trial Site

36 Registered trials

9 Currently recruiting

Organisation

Saint Maria Hospital

Location

Bucharest, Romania

Identifier

ORG-100023662

Address

Bulevardul Mihalache Ion 37-39, 011172, Romania

Departments

#2176: Rheumatology
#3304:Rheumatology
#3705: Rheumatology
3304; Rheumatology
3705: Rheumatology
9002: Rheumatology
Clinica de Medicina Interna si Reumatologie
Clinical Internal Medicine and Rheumatology
Gastroenterologie
Internal Medicine and Rheumatology
Internal Medicine I
N/A
NA
Reumathology
Rheumatology
Rheumatology and Internal Medicine I
Rheumatology Department
Rheumatology/Internal Medicine
Sectia clinica Reumatologie
Sectia de Reumatologie
Sectia Reumatologie

Clinical trials at this site (36)

Search interface

A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil… Not authorised

2022-501361-44-00 Adult patients of either gender with active moderate to 5
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with… Recruiting

2024-513965-38-01 Sjögren's Disease 5 2025-06-16
A Phase 3 Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis Recruiting

2022-500367-12-00 Dermatomyositis 5 2022-11-30
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E… Recruiting

2025-523552-31-00 Systemic Lupus Erythematosus 5 2026-05-07
Efficacy and Safety of IMVT-1402 in Adult Participants with Primary Sjogren’s Disease with Moderate to Severe Systemic Disease Activity Recruiting

2025-520831-18-00 Primary Sjogren’s Disease 4 2025-12-12
Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in participants With ANCA-associated Vasculitis Recruiting

2023-503184-42-00 Antineutrophil cytoplasmic antibody-associated vasculit 6 2025-07-28
A study to assess the efficacy and safety of efgartigimod PH20 SC in adults with systemic sclerosis (eSScape) Recruiting

2024-514539-67-00 Systemic Sclerosis 4 2025-06-27
Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS-… Recruiting

2023-505929-14-00 Systemic Lupus Erythematosus 5 2024-05-21
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1) Recruiting

2022-500699-76-00 Active Systemic Lupus Erythematosus (SLE) 5 2023-05-18
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic St… Recruiting

2023-510548-19-00 Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis 4 2023-03-02
A study to find if tibulizumab works and how safe it is in participants with systemic sclerosis Ended

2024-519335-42-01 Systemic Sclerosis 4 2025-12-22
Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease Ended

2024-516295-14-00 Treatment of Sjögren’s disease 4 2025-09-17
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
Determine effectiveness of Anifrolumab In Systemic sclerosis Ended

2023-505976-31-00 Systemic Sclerosis (SSc) presenting with Limited or Dif 5 2023-11-24
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic … Ended

2023-503655-10-00 Systemic Lupus Erythematosus (SLE). 5 2023-11-20
A Phase 3b/4 Randomized, Double-Blind, Double-Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib V… Ended

2022-502578-18-00 Rheumatoid Arthritis 11 2023-11-07
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’… Ended

2022-502966-26-01 Sjögren’s syndrome 5 2023-10-27
Phase 3 study to evaluate ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2) Ended

2023-508499-12-00 Systemic Lupus Erythematosus 5 2023-05-17
A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenanc… Ended

2023-509320-17-00 non-radiographic axial spondyloarthritis 6 2023-03-28
The WILLOW LTE study with enpatoran in participants with SCLE, DLE and/or SLE Ended

2024-510871-39-00 Systemic lupus erythematosus (SLE) and cutaneous lupus 4 2022-11-21
Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended

2024-511068-10-00 Sjögren’s Syndrome 5 2022-08-04
Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n… Ended

2023-508559-37-00 Lupus nephritis 5 2022-07-14
Efficacy and Safety of Afimetoran Compared with Placebo in Participants with Active Systemic Lupus Erythematosus Ended

2023-504320-25-00 Active Systemic Lupus Erythematosus 4 2021-11-25